US FDA clearance of Adherium’s Hailie for Teva inhalers

Adherium receives U.S. FDA 510(k) clearance for Teva’s ProAir® and Albuterol Sulphate inhaler users to remotely monitor physiological parametersMelbourne, Australia – 23 March 2023, Link Here : Adherium Limited (“Adherium”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, is pleased to announce that it has received U.S. Food and Drug […]

Adherium receives Australian TGA approval for Next Generation Sensors

Melbourne, Australia – Link Here: Adherium Limited (“Adherium”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, is pleased to announce receiving Australian Therapeutic Goods Administration (TGA) approval to commercially distribute its new, next generation Hailie® sensors with physiological parameters. These latest additions to the Hailie sensor product family connect patients […]

Adherium receives U.S. FDA 510(k) clearance for GSK pMDI inhaler users to remotely monitor physiological parameters

Melbourne, Australia – 28 November 2022: (Link Here) Adherium Limited (“Adherium”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced that is has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market application, connecting GlaxoSmithKline’s (GSK) Ventolin®, Advair®, and Flovent® pressurised metered dose inhaler (pMDI) users with […]

Adherium appoints Daniel Kaplon as Chief Financial Officer

Melbourne, Australia – 21 September 2022 Link here : Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce the appointment of Mr Daniel Kaplon as Chief Financial Officer, effective 10 October 2022. Mr Rick Legleiter, Adherium Chief Executive Officer, commented, “we are very pleased to […]

Clinical Study involving new Hailie Sensor with Physiological Parameters Launched in U.S.

Melbourne, Australia – 20 September 2022 Link here : Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce a two-part clinical study at Washington University School of Medicine in St. Louis in the United States to monitor the adherence of Asthma patients using Adherium’s US […]

Adherium secures A$13.5 million commitment in share and option placement

Melbourne, Australia Link Here – 16 September 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, has secured subscription commitments from the Company’s Chairman, new and existing institutional and sophisticated investors, including cornerstone investments from existing shareholders Trudell Medical and BioScience Managers Translation Fund […]

Adherium and CareCentra Team Up to Develop a Respiratory Risk Management System

Melbourne, Australia Link Here – 13 September 2022: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce a platform partnership with CareCentra Inc. to improve COPD (Chronic Obstructive Pulmonary Disease) and Asthma care by creating a truly transformative disease management suite. CareCentra will integrate Adherium’s […]

Adherium agreement signed with Dulcian Health for US remote patient monitoring

Melbourne, Australia Link here – 9 September 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote patient monitoring and data management solutions, is pleased to announce a partnership agreement with Dulcian Health (“Dulcian”) to deploy the Hailie® platform enabling doctors and medical groups in the US to access reimbursement […]

Adherium submits FDA 510(k) application for next generation Hailie sensor for Teva MDI inhalers

Melbourne, Australia Link Here – 25 August 2022: Adherium Limited (“Adherium” or “the  Company”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced submission to the US Food and Drug Administration (FDA) of its 510(k) clearance to market application, which connects Teva ProAir® and Teva Albuterol Sulphate HFA metered […]

Adherium to present at Reach Markets ‘Meet the CEOs’ live event

Melbourne, Australia / Link here – 16 August 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, is pleased to announce its participation in the Reach Markets ‘Meet the CEOs’ live event, being held tomorrow, Wednesday 17th of August 2022. The webinar will open […]